Xiaobin Wu - BeiGene President COO
| BGNE Stock | USD 205.75 9.25 4.30% |
President
Dr. Xiaobin Wu is General Manager, China and President of the Company. He joined our Company in April 2018 as our General Manager, China and President. He has more than 25 years of experience in the pharmaceutical industry, including 17 years leading China operations of multinational companies, with expertise in research and development, strategy, commercialization and general management. Before joining the Company in April 2018, Dr. Wu served as the Country Manager of Pfizer China from 2009 to April 2018 and Regional President of Pfizer Essential Health in the Greater China Region from 2017 to April 2018. Under his leadership, Pfizer China experienced significant growth to become a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from 2004 to 2009. Before joining Wyeth, Dr. Wu served as the General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany since 2018.
| Age | 62 |
| Tenure | 6 years |
| Address | 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108 |
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
Latest Insider Transactions
Wu has served as a Vice Chairman of the R&D Based Pharmaceutical Association Committee in China since 2008. He also serves as Vice Chairman of the Pharmaceutical Chamber of Commerce of China’s National Association of Industry & Commerce, and Executive Vice Chairman of the Chinese Pharmaceutical Enterprise Association. He is also a research fellow at the Research Center of National Drug Policy and Ecosystem of China Pharmaceutical University in Nanjing, China.Xiaobin Wu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Xiaobin Wu against BeiGene stock is an integral part of due diligence when investing in BeiGene. Xiaobin Wu insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Xiaobin Wu over a year ago BeiGene exotic insider transaction detected | ||
Xiaobin Wu over a year ago Acquisition by Xiaobin Wu of 200447 shares of BeiGene subject to Rule 16b-3 | ||
Xiaobin Wu over a year ago BeiGene exotic insider transaction detected |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 37.5 M, whereas Other Assets are forecasted to decline to 1.90.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Andrew MBA | Vaxcyte | 56 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Scott Smith | Ascendis Pharma AS | 50 | |
| Wade Walke | Ionis Pharmaceuticals | N/A | |
| Dashyant Dhanak | Incyte | 63 | |
| Frank Bennett | Ionis Pharmaceuticals | 67 | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Flemming Jensen | Ascendis Pharma AS | 63 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, CoChairman CoFounder | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Daniel Maller, VP Accounting | ||
| Jaspreet MD, Senior Strategy | ||
| Diana Francis, VP Compliance | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 22.24 B | ||||
| Shares Outstanding | 97.43 M | ||||
| Shares Owned By Insiders | 19.46 % | ||||
| Shares Owned By Institutions | 49.23 % | ||||
| Number Of Shares Shorted | 999.4 K | ||||
| Price To Earning | (16.19) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.19) | Revenue Per Share 225.239 | Quarterly Revenue Growth 0.395 | Return On Assets (0.1) | Return On Equity (0.23) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.